ABSTRACT: Growth hormones are proteins produced by the anterior pituitary gland responsible for bone and tissue growth through their
effects on carbohydrates, lipids and proteins metabolisms. Despite strict regulations banning the use of recombinant equine
growth hormone, this substance is suspected to be misused to improve the horse physical performances. In order to check whether
the regulation is fulfilled or not, controls are organized and a new analytical screening tool potentially able to detect
such abuse was investigated in this paper. An untargeted metabolomics approach, based on liquid chromatography coupled to
high resolution mass spectrometry, was developed and applied to characterize and compare horse urinary and plasmatic metabolic
profiles upon reGH administrations. After minimal sample preparation, biological fluids were analyzed by LC-ESI(±)-Q-TOF.
Data processing was performed by XCMS software and multivariate data analysis applied to the generated data set allowed building
OPLS models to discriminate control versus treated populations. Results demonstrated significant metabolic modifications consecutively
to the reGH treatment. A comparative study between urinary and plasmatic signatures was performed to evaluate the resulting
metabolomic models and to asses their respective interests in the scope of real application for screening reGH administration.
KeywordsGrowth hormone–Horse racing–High resolution mass spectrometry–Metabolomics
Metabolomics 04/2012; 7(1):84-93. · 4.51 Impact Factor